Alvotech Earnings Call Transcripts
Fiscal Year 2026
-
The company is positioned for significant growth with a robust biosimilar pipeline, strong global partnerships, and recent regulatory progress. Key launches for SIMPONI, EYLEA, and Entyvio are on track, supported by expanded manufacturing and a focus on limited-competition markets.
-
The company is at a pivotal stage, having addressed FDA facility concerns and resubmitted key BLAs, with multiple U.S. launches expected by year-end. Its pipeline targets high-value biosimilars like Entyvio and Eylea, supported by expanded manufacturing and a strategy to be first-to-market in major categories.
-
The company is accelerating U.S. launches with recent FDA resubmissions and expects five products on the U.S. market by year-end. Expanded manufacturing through a Fujifilm partnership supports a robust pipeline, with first-to-market ambitions for key biosimilars like ENTYVIO and high-dose Eylea. 2026 guidance projects strong revenue and EBITDA growth.
-
Recent launches and a robust pipeline position the company for limited-competition biosimilar entries, with regulatory remediation on track for key approvals by year-end. Expanded manufacturing and strategic partnerships support growth, while industry consolidation and regulatory changes enhance competitive positioning.
-
Q1 2026 saw revenues decline 20% year-over-year to $106 million due to facility improvements, but gross margin improved and EBITDA margin rose to 23%. Regulatory progress, new launches, and a strategic FUJIFILM partnership position the company for strong growth in 2027.
Fiscal Year 2025
-
2025 saw 21% revenue growth to $593M and 27% higher adjusted EBITDA, driven by licensing and new launches. Guidance for 2026 is $650–$700M revenue, with U.S. launches providing upside. Regulatory remediation and expanded manufacturing underpin future growth.
-
Strong revenue and EBITDA growth are forecast for 2025 and 2026, supported by robust product launches, expanding global partnerships, and a diversified biosimilar pipeline. Regulatory issues are being addressed, with continued investment in R&D and operational efficiency.
-
A global biosimilar leader is expanding from two to six marketed products, with a robust pipeline and strong partnerships driving growth. Despite a temporary production slowdown for FDA remediation, EBITDA remains positive, and revenue is projected to reach $600M in 2024. Regulatory and industry shifts are expected to support further expansion.
-
Revenue grew 24% year-on-year to $420 million for the first nine months of 2025, with strong licensing and product momentum. Facility improvements following an FDA CRL temporarily impacted production, but 93% of corrective actions are complete and guidance remains robust for 2025 and 2026.
-
A robust global expansion is underway, with a transition to a broader biosimilar portfolio and strong growth in both the U.S. and international markets. Revenue and margin growth are expected as new products launch and regulatory changes streamline development, while the company maintains high barriers to entry and a selective partnership approach.
-
Strong first-half results with 30% revenue growth and robust product sales, driven by biosimilar launches and market share gains in the U.S. and Europe. Guidance for full-year revenue and EBITDA remains unchanged, with a strong Q4 expected.
-
Alvotech is leveraging a vertically integrated platform and global partnerships to drive biosimilar launches, with a robust pipeline targeting $1.5 billion revenue and 40–45% EBITDA margin by 2028. Recent acquisitions, expanded guidance, and a self-funding R&D model position the company for sustained growth.
-
A vertically integrated biosimilars company outlined a global growth strategy, robust pipeline, and ambitious financial targets through 2028, leveraging regional partnerships and recent acquisitions to expand R&D and market reach. New launches and operational efficiency are expected to drive revenues and margins.
-
A global biosimilars player leverages a partnership-driven model, robust pipeline, and in-house manufacturing to drive growth and efficiency. Financial targets include $1.5B revenue and 40–45% EBITDA margin by 2028, with strong performance in both U.S. and ex-U.S. markets.
-
Q1 2025 saw a 784% year-over-year revenue increase, positive adjusted EBITDA, and raised full-year guidance to $600–$700 million in revenue and $200–$280 million in adjusted EBITDA. Biosimilar launches in the U.S. and Europe drove growth, with strong order books and expanding market share.
-
Management highlighted robust global expansion, strong product launches for Humira and Stelara biosimilars, and a pipeline targeting a $200 billion market. Revenue guidance for 2025 is $600–$800 million, driven by new launches, milestone revenues, and growing ex-US business.
Fiscal Year 2024
-
2024 saw over 400% revenue growth, positive EBITDA, and major product launches, with strong U.S. and EU biosimilar market gains. Guidance for 2025 projects continued double-digit growth, margin expansion, and three new global launches, supported by a robust pipeline and strategic acquisitions.
-
Biosimilar launches are accelerating globally, with major products like Humira and Stelara driving revenue growth and market expansion. Financially, leverage is managed with maturities extended to 2029, and the company is nearing cash flow positivity.
-
A pure-play biosimilar company has built a global platform with $1.9 billion invested, 11 products in its pipeline, and strong commercial partnerships covering 95% of branded biologic markets. With scalable operations and multiple launches ahead, it targets industry leadership and sustained profitable growth.
-
Revenues for the first nine months of 2024 surged nearly ninefold year-over-year, driven by strong product launches and milestone revenues. Product margins improved significantly, and the company expects a robust Q4, with some shipments possibly spilling into 2025.
-
Rapid expansion in biosimilars is underway, with strong order growth, new private label deals, and robust financial performance. Manufacturing capacity is scaling up, and the pipeline is advancing with multiple global launches planned. Industry consolidation and evolving regulatory trends support long-term growth.
-
Record H1 2024 revenues and positive EBITDA were driven by US Humira and ex-US Stelara biosimilar launches, with strong order book growth and robust pipeline progress. Guidance for 2024 remains $400–$500 million in revenue and $100–$150 million adjusted EBITDA.
-
A vertically integrated biosimilar leader, the company leverages a global B2B model and strong partnerships to launch a broad portfolio across major markets. With first-mover advantages in key products and a robust pipeline, it targets $400M–$500M revenue and $100M–$150M EBITDA in 2024.